» Articles » PMID: 29250455

Changes in Urinary Metabolic Profiles of Colorectal Cancer Patients Enrolled in a Prospective Cohort Study (ColoCare)

Overview
Journal Metabolomics
Publisher Springer
Specialty Endocrinology
Date 2017 Dec 19
PMID 29250455
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Metabolomics is a valuable tool for biomarker screening of colorectal cancer (CRC). In this study, we profiled the urinary metabolomes of patients enrolled in a prospective patient cohort (ColoCare). We aimed to describe changes in the metabolome in the longer clinical follow-up and describe initial predictors as candidate markers with possibly prognostic significance.

Methods: In total, 199 urine samples from CRC patients pre-surgery (n=97), 1-8 days post-surgery (n=12) and then after 6 and 12 months (n=52 and 38, respectively) were analyzed using both GC-MS and H-NMR. Both datasets were analyzed separately with built in uni- and multivariate analyses of Metaboanalyst 2.0. Furthermore, adjusted linear mixed effects regression models were constructed.

Results: Many concentrations of the metabolites derived from the gut microbiome were affected by CRC surgery, presumably indicating a tumor-induced shift in bacterial species. Associations of the microbial metabolites with disease stage indicate an important role of the gut microbiome in CRC.We were able to differentiate the metabolite profiles of CRC patients prior to surgery from those at any post-surgery timepoint using a multivariate model containing 20 marker metabolites (AUCROC=0.89; 95% CI:0.84-0.95).

Conclusion: To the best of our knowledge, this is one of the first metabolomic studies to follow CRC patients in a prospective setting with repeated urine sampling over time. We were able to confirm markers initially identified in case-control studies and pin point metabolites which may serve as candidates for prognostic biomarkers of CRC.

Citing Articles

Sample Preparation for Metabolomic Analysis in Exercise Physiology.

Nakhod V, Butkova T, Malsagova K, Petrovskiy D, Izotov A, Nikolsky K Biomolecules. 2025; 14(12.

PMID: 39766268 PMC: 11673972. DOI: 10.3390/biom14121561.


The Potential of Metabolomics in Colorectal Cancer Prognosis.

Fu C, Liu X, Wang L, Hang D Metabolites. 2024; 14(12).

PMID: 39728489 PMC: 11677167. DOI: 10.3390/metabo14120708.


Metabolomics analyses of cancer tissue from patients with colorectal cancer.

Kang C, Zhang J, Xue M, Li X, Ding D, Wang Y Mol Med Rep. 2023; 28(5).

PMID: 37772396 PMC: 10568249. DOI: 10.3892/mmr.2023.13106.


Cohort profile: Biomarkers related to folate-dependent one-carbon metabolism in colorectal cancer recurrence and survival - the FOCUS Consortium.

Gigic B, van Roekel E, Holowatyj A, Brezina S, Geijsen A, Ulvik A BMJ Open. 2022; 12(12):e062930.

PMID: 36549742 PMC: 9772678. DOI: 10.1136/bmjopen-2022-062930.


Urine NMR Metabolomics for Precision Oncology in Colorectal Cancer.

Brezmes J, Llambrich M, Cumeras R, Guma J Int J Mol Sci. 2022; 23(19).

PMID: 36232473 PMC: 9569997. DOI: 10.3390/ijms231911171.


References
1.
Nishiumi S, Kobayashi T, Ikeda A, Yoshie T, Kibi M, Izumi Y . A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One. 2012; 7(7):e40459. PMC: 3394708. DOI: 10.1371/journal.pone.0040459. View

2.
Carman R, Van Tassell R, Kingston D, Bashir M, Wilkins T . Conversion of IQ, a dietary pyrolysis carcinogen to a direct-acting mutagen by normal intestinal bacteria of humans. Mutat Res. 1988; 206(3):335-42. DOI: 10.1016/0165-1218(88)90119-x. View

3.
Ma Y, Qin H, Liu W, Peng J, Huang L, Zhao X . Ultra-high performance liquid chromatography-mass spectrometry for the metabolomic analysis of urine in colorectal cancer. Dig Dis Sci. 2009; 54(12):2655-62. DOI: 10.1007/s10620-008-0665-4. View

4.
Yamanishi Y, Iguchi M, Oyama H, Matsumura Y . Collagen metabolism. I. Significance of urinary pyrrole-2-carboxylic acid. J Clin Endocrinol Metab. 1972; 35(1):55-8. DOI: 10.1210/jcem-35-1-55. View

5.
Kondo Y, Nishiumi S, Shinohara M, Hatano N, Ikeda A, Yoshie T . Serum fatty acid profiling of colorectal cancer by gas chromatography/mass spectrometry. Biomark Med. 2011; 5(4):451-60. DOI: 10.2217/bmm.11.41. View